Role of elevated cancer antigen 19-9 in women with mature cystic teratoma

Marina Frimer, Brandon Luke L Seagle, Scott Chudnoff, Gary L. Goldberg, Shohreh Shahabi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objective of this study was to determine how often an elevated cancer antigen (CA) 19-9 (≥ 37 U/mL) was present during the preoperative evaluation of women with a mature cystic teratoma (MCT). This was a retrospective, consecutive case series (N = 139) of histologically proven MCT treated at Montefiore Medical Center from 1997 to 2008. Data were analyzed for patient and tumor characteristics, tumor markers (CA 19-9, CA 125, and carcinoembryonic antigen [CEA]), preoperative imaging, and procedure. CA 19-9 was elevated in 37.4% of patients. Elevated CA 19-9 was not significantly associated with age, race, CA 125 (≥35 U/mL), CEA (≥5 ng/mL), MCT size, or the presence of bilateral MCTs. Of the patients, 59% were ≥40 years old. Age <40 years was associated with cystectomy rather than oophorectomy (P <.001), regardless of CA 19-9 (P =.09). Elevated preoperative CA 19-9 in patients with MCT was associated with increased preoperative computed tomography (P =.04).

Original languageEnglish (US)
Pages (from-to)1307-1311
Number of pages5
JournalReproductive Sciences
Volume21
Issue number10
DOIs
StatePublished - Oct 11 2014

Fingerprint

Teratoma
Antigens
Neoplasms
Carcinoembryonic Antigen
Preoperative Care
Cystectomy
Differentiation Antigens
Ovariectomy
Neoplasm Antigens
Tumor Biomarkers
Tomography

Keywords

  • adnexal mass
  • CA 19-9
  • ovarian tumor
  • teratoma
  • tumor marker

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Frimer, M., Seagle, B. L. L., Chudnoff, S., Goldberg, G. L., & Shahabi, S. (2014). Role of elevated cancer antigen 19-9 in women with mature cystic teratoma. Reproductive Sciences, 21(10), 1307-1311. https://doi.org/10.1177/1933719114525274

Role of elevated cancer antigen 19-9 in women with mature cystic teratoma. / Frimer, Marina; Seagle, Brandon Luke L; Chudnoff, Scott; Goldberg, Gary L.; Shahabi, Shohreh.

In: Reproductive Sciences, Vol. 21, No. 10, 11.10.2014, p. 1307-1311.

Research output: Contribution to journalArticle

Frimer, M, Seagle, BLL, Chudnoff, S, Goldberg, GL & Shahabi, S 2014, 'Role of elevated cancer antigen 19-9 in women with mature cystic teratoma', Reproductive Sciences, vol. 21, no. 10, pp. 1307-1311. https://doi.org/10.1177/1933719114525274
Frimer M, Seagle BLL, Chudnoff S, Goldberg GL, Shahabi S. Role of elevated cancer antigen 19-9 in women with mature cystic teratoma. Reproductive Sciences. 2014 Oct 11;21(10):1307-1311. https://doi.org/10.1177/1933719114525274
Frimer, Marina ; Seagle, Brandon Luke L ; Chudnoff, Scott ; Goldberg, Gary L. ; Shahabi, Shohreh. / Role of elevated cancer antigen 19-9 in women with mature cystic teratoma. In: Reproductive Sciences. 2014 ; Vol. 21, No. 10. pp. 1307-1311.
@article{8fbea0b9e05f499fbc7e253ee31f36d2,
title = "Role of elevated cancer antigen 19-9 in women with mature cystic teratoma",
abstract = "The objective of this study was to determine how often an elevated cancer antigen (CA) 19-9 (≥ 37 U/mL) was present during the preoperative evaluation of women with a mature cystic teratoma (MCT). This was a retrospective, consecutive case series (N = 139) of histologically proven MCT treated at Montefiore Medical Center from 1997 to 2008. Data were analyzed for patient and tumor characteristics, tumor markers (CA 19-9, CA 125, and carcinoembryonic antigen [CEA]), preoperative imaging, and procedure. CA 19-9 was elevated in 37.4{\%} of patients. Elevated CA 19-9 was not significantly associated with age, race, CA 125 (≥35 U/mL), CEA (≥5 ng/mL), MCT size, or the presence of bilateral MCTs. Of the patients, 59{\%} were ≥40 years old. Age <40 years was associated with cystectomy rather than oophorectomy (P <.001), regardless of CA 19-9 (P =.09). Elevated preoperative CA 19-9 in patients with MCT was associated with increased preoperative computed tomography (P =.04).",
keywords = "adnexal mass, CA 19-9, ovarian tumor, teratoma, tumor marker",
author = "Marina Frimer and Seagle, {Brandon Luke L} and Scott Chudnoff and Goldberg, {Gary L.} and Shohreh Shahabi",
year = "2014",
month = "10",
day = "11",
doi = "10.1177/1933719114525274",
language = "English (US)",
volume = "21",
pages = "1307--1311",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Role of elevated cancer antigen 19-9 in women with mature cystic teratoma

AU - Frimer, Marina

AU - Seagle, Brandon Luke L

AU - Chudnoff, Scott

AU - Goldberg, Gary L.

AU - Shahabi, Shohreh

PY - 2014/10/11

Y1 - 2014/10/11

N2 - The objective of this study was to determine how often an elevated cancer antigen (CA) 19-9 (≥ 37 U/mL) was present during the preoperative evaluation of women with a mature cystic teratoma (MCT). This was a retrospective, consecutive case series (N = 139) of histologically proven MCT treated at Montefiore Medical Center from 1997 to 2008. Data were analyzed for patient and tumor characteristics, tumor markers (CA 19-9, CA 125, and carcinoembryonic antigen [CEA]), preoperative imaging, and procedure. CA 19-9 was elevated in 37.4% of patients. Elevated CA 19-9 was not significantly associated with age, race, CA 125 (≥35 U/mL), CEA (≥5 ng/mL), MCT size, or the presence of bilateral MCTs. Of the patients, 59% were ≥40 years old. Age <40 years was associated with cystectomy rather than oophorectomy (P <.001), regardless of CA 19-9 (P =.09). Elevated preoperative CA 19-9 in patients with MCT was associated with increased preoperative computed tomography (P =.04).

AB - The objective of this study was to determine how often an elevated cancer antigen (CA) 19-9 (≥ 37 U/mL) was present during the preoperative evaluation of women with a mature cystic teratoma (MCT). This was a retrospective, consecutive case series (N = 139) of histologically proven MCT treated at Montefiore Medical Center from 1997 to 2008. Data were analyzed for patient and tumor characteristics, tumor markers (CA 19-9, CA 125, and carcinoembryonic antigen [CEA]), preoperative imaging, and procedure. CA 19-9 was elevated in 37.4% of patients. Elevated CA 19-9 was not significantly associated with age, race, CA 125 (≥35 U/mL), CEA (≥5 ng/mL), MCT size, or the presence of bilateral MCTs. Of the patients, 59% were ≥40 years old. Age <40 years was associated with cystectomy rather than oophorectomy (P <.001), regardless of CA 19-9 (P =.09). Elevated preoperative CA 19-9 in patients with MCT was associated with increased preoperative computed tomography (P =.04).

KW - adnexal mass

KW - CA 19-9

KW - ovarian tumor

KW - teratoma

KW - tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84908888224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908888224&partnerID=8YFLogxK

U2 - 10.1177/1933719114525274

DO - 10.1177/1933719114525274

M3 - Article

VL - 21

SP - 1307

EP - 1311

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 10

ER -